Ceritinib is not the same target as alectinib. Ceritinib is used in patients with locally advanced or metastatic non-small cell lung cancer that has progressed after prior treatment with crizotinib or is crizotinib intolerant who are locally advanced or metastatic with anaplastic lymphoma kinase positivity. Its inhibitory targets include anaplastic lymphoma kinase (ALK), insulin-like growth factor-1 receptor, insulin receptor, and tyrosine kinase receptor. Adverse reactions such as diarrhea, nausea and vomiting may occur after use. Patients who are allergic to any of the active ingredients or excipients of the product need to be contraindicated. And alectinib is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with kinase-positive mesenchymal lymphoma. Its inhibitory target is mainly the mesenchymal lymphoma kinase fusion gene. Therefore, Ceritinib is not the same target as alectinib. Adverse reactions such as constipation, nausea, and edema can occur after use, and prompt medical attention is recommended. It is contraindicated in patients with known hypersensitivity to alectinib or any excipients of the product. Patients are advised to use Ceritinib and Aleitinib under the supervision of a doctor and not to use them privately.